Prediction of Hyperkalemia in Dialysis Patients Through Waveform Analysis Using Wearable ECG
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Daejeon, South Korea
- Chungnam National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults aged 19 years or older
- Diagnosed with chronic kidney disease (CKD) and receiving maintenance hemodialysis three times per week
- Stable clinical condition without acute complications in the past 3 months
- Ability to understand and sign informed consent
- No physical or physiological barrier to wearing an ECG device
Exclusion Criteria:
- Significant skin conditions (e.g., severe dermatitis, burns) that prevent ECG device attachment
- Refusal or inability to comply with study procedures
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Hemodialysis Patients
Adults with chronic kidney disease receiving maintenance hemodialysis three times per week.
Participants will wear a HiCardi single-lead wearable ECG device during dialysis sessions for 8 weeks.
ECG data will be collected four times in coordination with routine blood potassium tests to evaluate the correlation between ECG waveform changes and hyperkalemia.
|
A chest-attached, single-lead wearable ECG device used to collect real-time ECG data from hemodialysis patients.
The device records ECG waveforms during dialysis sessions and transmits the data to a secure cloud platform.
This non-invasive tool is used to analyze T-wave morphology for early detection of hyperkalemia in patients with chronic kidney disease.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between EKG characteristics and serum potassium level
Time Frame: Week 0, Week 2, Week 4, Week 6
|
The primary outcome is the correlation between EKG characteristics (e.g., T wave amplitude, QRS duration, P wave morphology) measured using a wearable single-lead ECG device and serum potassium levels obtained from blood tests.
Data will be collected at four time points over 8 weeks.
|
Week 0, Week 2, Week 4, Week 6
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Metabolic Diseases
- Renal Insufficiency
- Water-Electrolyte Imbalance
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Renal Insufficiency, Chronic
- Hyperkalemia
Other Study ID Numbers
Other Study ID Numbers
- CNUH 2025-05-023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.